UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Amidst the blockbuster success of its weight-loss drugs, pharmaceutical giant Eli Lilly is making a strategic push into genetic medicine, securing exclusive rights to novel hearing loss treatments through a major partnership with German biotech Seamless Therapeutics.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Morgan Stanley has secured the leading position as a financial adviser for mergers and acquisitions in the global power sector for 2025, advising on deals worth a combined $63.4 billion, according to new industry data.
Swedish industrial giant Alfa Laval has put mergers and acquisitions back at the top of its agenda, telling investors it is actively hunting for deals to expand its footprint in energy transition and service markets, even as it navigates internal restructuring.
Sullivan & Cromwell advised on the highest-value deals in the consumer sector last year, while Kirkland & Ellis worked on the greatest number of transactions, according to new data from GlobalData.
PrimeGen US, a regenerative medicine company, has agreed to merge with special purpose acquisition company DT Cloud Star in a deal valued at approximately $1.5 billion, aiming to accelerate its stem cell therapy development and secure public market funding.
Performance Food Group is actively pursuing acquisitions to bolster long-term growth, its CFO confirmed, signaling a strategic push to expand scale and reach even as the company navigates near-term earnings challenges.
Investment bank Moelis & Company outperformed analyst expectations for Q4 2025, reporting an 11.2% year-over-year revenue increase to $487.9 million. The firm credits robust dealmaking, a record capital markets year, and strategic hiring for its momentum.
New long-term data for Ultragenyx Pharmaceutical's UX111 gene therapy shows promise in halting cognitive decline in Sanfilippo syndrome type A, coinciding with a key FDA resubmission. While the development marks a significant scientific advance, it unfolds against a backdrop of persistent financial pressures for the company.
Amgen's stock has surged over 27% in the past year, prompting investors to scrutinize whether its current price still reflects the underlying business value. A deep dive into cash flow and earnings models suggests a potential disconnect.
Sagimet Biosciences shares are back in focus following positive late-stage trial results for its acne drug candidate Denifanstat. With the stock showing volatile performance but a promising long-term return, investors are weighing its current valuation against significant future potential and inherent pipeline risks.
Oaktree Specialty Lending (OCSL) reported stable earnings for its fiscal first quarter, with adjusted net investment income rising to $0.41 per share. Management highlighted disciplined capital deployment, a focus on reducing non-accruals, and detailed the firm's evolving approach to underwriting software and AI-related risks in a bifurcated market.
OpenAI's proposal to trade its AI software for a cut of future drug revenues faces steep odds, analysts say, as the real bottlenecks in medicine lie far beyond the discovery phase.
TransDigm Group concluded fiscal 2024 with robust cash reserves nearing $6.3 billion, powered by high-margin aftermarket revenues. While navigating Boeing strike impacts and a slower OEM recovery, the aerospace supplier projects steady growth for 2025 and signals continued aggressive capital deployment for acquisitions and shareholder returns.
Twist Bioscience shares have surged over 40% in the past month, reigniting investor debate. While short-term momentum is strong, the stock's long-term performance and a significant gap between its market price and some fair value estimates present a complex picture for the synthetic biology firm.
Kyivstar Group's successful secondary offering on Nasdaq has bolstered its war chest, enabling a sharper pivot towards building a digital ecosystem and pursuing strategic acquisitions beyond its core telecom operations.
Shares of Viking Therapeutics have retreated sharply from recent highs, presenting a conundrum for investors. While short-term performance lags, long-term gains remain stellar. We delve beyond the headline numbers, using DCF and peer analysis to assess if the current weakness is a buying opportunity.
As the offshore drilling sector tightens, Seadrill Limited emerges as a focal point for investors betting on industry consolidation and asset repricing. This analysis unpacks the bullish case centered on its modern fleet and compelling takeover appeal.
Giverny Capital has spotlighted Medpace Holdings' aggressive share repurchase program as a vote of confidence, as the contract research organization navigates persistent concerns over biopharmaceutical funding. The firm's strategy highlights a broader debate on capital allocation in a volatile sector.
